Business
Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
SAN DIEGO, April 14, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present at the Internation Oncolytic Virus Conference (IOVC) in Reykjavik, Iceland on April 28th, 2026. The Company will present data on its RedTail platform and its lead compound CLD-401. RedTail is Calidi’s systemically delivered virotherapy platform designed to selectively target tum
About this update from Calidi Biotherapeutics, Inc.
[{"type":"image","alt":"Calidi Biotherapeutics, Inc","displaySize":"","headline":null,"caption":"Calidi Biotherapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wX9t4eJfVQL9R1_CtWiapg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMA--/https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1","width":300,"height":93}},"lazy":false},{"type":"text","content":"SAN DIEGO, April 14, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present at the Internation Oncolytic Virus Conference (IOVC) in Reykjavik, Iceland on April 28th, 2026. The Company will present data on its RedTail platform and its lead compound CLD-401.","length":401,"tagName":"p"},{"type":"text","content":"RedTail is Calidi’s systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads directly at the tumor site while limiting peripheral exposure. Data presented at IOVC by Duong Nguyen, PhD, Senior Director, Translational Research and Innovation for Calidi, will showcase the ability of the RedTail extracellular enveloped and CD55-overexpressing virus (EEV) to avoid immune clearance, replicate only in target cells, and deliver high concentrations of genetic medicine to sites of disease.","length":617,"tagName":"p"},{"type":"text","content":"CLD-401, the lead candidate derived from the RedTail platform, is engineered to express high levels of IL-15 superagonist (IL-15 SA), a known T and NK-cell activator, in the TME. The Company expects to file an IND for CLD-401 by the end of 2026. Additionally, Calidi is expanding the RedTail platform to enable in situ expression of T-cell engagers (TCEs) in solid tumors, including in combination with T-cell activating payloads such as IL15 SA. This strategy is intended to support localized T-cell engagement within the TME following systemic administration. The Company is developing CLD-501, a RedTail virus that expresses high levels of a TROP2-targeting TCE and IL-15SA in the TME.","length":688,"...